How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review

Abstract

A large number of clinical measures of psoriasis are used in clinical trials and daily practice. These measures lack uniformity and validation. However, valid outcome and severity measures for psoriasis are a prerequisite for fully informative clinical research and evidence-based medicine. The purpose of this study was to identify all clinical measures of psoriasis severity and outcome in use and to evaluate the quality of these measures using clinimetric criteria; we identified 53 separate clinical measures, which were regrouped into 11 measures for quality analysis. No measure could be scored on all items used in the clinimetric analysis. The Lattice System Physician's Global Assessment and Physician's Global Assessment were most highly noted. We conclude that none of the psoriasis measures is adequately validated. The Psoriasis Area and Severity Index is the most commonly used clinical measure in research, but it has substantial limitations such as low response distribution, no consensus on interpretability, and low responsiveness in mild disease. Nevertheless, because of its widespread use the Psoriasis Area and Severity Index permits some degree of comparison of results among clinical trials. Overall, no best instrument was identified, and different situations may call for different measures.

Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

“…The PASI has some limitations, but it is relevant from the patient's perspective and is the most widely used outcome measure in psoriasis trials, thus allowing us to perform meta-analysis. 66 When interpreting and comparing any psoriasis trial data, the methods of handling missing data have to be taken into consideration. The use of different imputation models can have an important impact on the results.…”

Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT

“…The PGA is well accepted by practicing clinicians and has been reported to have good interrater reliability, and it does not appear to be influenced by the amount of rater experience 25 * n = 69 for placebo; n = 67 for adalimumab. ** n = 60 for placebo; n = 62 for adalimumab.…”

Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity

“…Psoriasis severity is frequently evaluated in clinical trials using the Psoriasis Area and Severity Index (PASI), the Physician's Global Assessment, and an estimate of the body surface area (BSA) affected by psoriasis (1)(2)(3). In addition to clinical measures, patient-reported outcomes (PROs) are important to understand the patient's perspective of disease (4,5).…”